Editas Medicine, Inc. is a clinical-stage company dedicated to developing innovative genomic medicines that address a range of serious diseases. The company utilizes its proprietary gene editing platform, which is founded on CRISPR technology. Its robust pipeline includes EDIT-101, currently undergoing Phase 1/2 clinical trials for Leber Congenital Amaurosis 10, a genetic condition causing childhood blindness.